<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117738</url>
  </required_header>
  <id_info>
    <org_study_id>AST-ADP2-US01</org_study_id>
    <nct_id>NCT03117738</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease</brief_title>
  <official_title>A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nature Cell Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nature Cell Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in&#xD;
      subjects with Alzheimer's Disease. Following first screening period, subjects will be&#xD;
      randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1&#xD;
      ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure&#xD;
      will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up&#xD;
      visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Related Adverse Events</measure>
    <time_frame>30 Weeks</time_frame>
    <description>Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE (Mini-mental Status Examination)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR-SOB (Clinical Dementia Rating-Sum of Boxes)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPI (Neuropsychiatric Inventory)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GDS (Geriatric Depression Scale)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-SSRS (Columbia Suicide Severity Rating Scale)</measure>
    <time_frame>Baseline and 30 Weeks</time_frame>
    <description>Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>AstroStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AstroStem</intervention_name>
    <description>Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
    <arm_group_label>AstroStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-Control</intervention_name>
    <description>Saline with 30% auto-serum</description>
    <arm_group_label>Placebo-Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged 50 and above at the time of signing the Informed Consent&#xD;
             form&#xD;
&#xD;
          -  Subjects who can understand and provide written informed consent (assent)&#xD;
&#xD;
          -  Subjects who have diagnosis of probable mild-to-moderate Alzheimer disease according&#xD;
             to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and&#xD;
             Stroke; Alzheimer's Disease and Related Disorders Association) criteria&#xD;
&#xD;
          -  Subjects who have MMSE Score of 16 to 26 at screening&#xD;
&#xD;
          -  Subjects who are taking FDA-approved AD medications (donepezil, galantamine,&#xD;
             memantine, rivastigmine or their combinations) treatment on a stable dosage for at&#xD;
             least 3 months prior to screening.&#xD;
&#xD;
          -  Subjects who have one (or more) identified adult caregiver who is able to read,&#xD;
             understand, and speak the designated language at the study site; either lives with the&#xD;
             subject or sees the subject for ≥2 hours/day ≥4 days/week; and agrees to accompany the&#xD;
             subject to each study visit&#xD;
&#xD;
          -  Subjects who have a designated study partner who will accompany the subject to all&#xD;
             clinic visits and participate in the subject's clinical assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are females who are pregnant, nursing, or of childbearing potential while&#xD;
             not practicing effective contraception&#xD;
&#xD;
          -  Subjects who have signs of delirium&#xD;
&#xD;
          -  Subjects who have had cortical stroke within the preceding 2 years&#xD;
&#xD;
          -  Subjects who have a prolonged QTc interval; &gt;450 msec in male or &gt;470 msec in female&#xD;
             at screening&#xD;
&#xD;
          -  Subjects who have diagnosis of severe white matter hyperintensity (WMH), which is&#xD;
             defined as ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular&#xD;
             capping/banding in lengths&#xD;
&#xD;
          -  Subjects who have diagnosis of dementia or cause of cognitive impairment other than&#xD;
             Alzheimer's disease&#xD;
&#xD;
          -  Subjects who have a significant abnormal result in laboratory tests, in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Subjects who have participated in any investigational drug, stem cell therapy, or&#xD;
             device trial within the previous 3 months at screening&#xD;
&#xD;
          -  Subjects with any current psychiatric diagnosis other than AD if, in the judgment of&#xD;
             the investigator, the psychiatric disorder or symptom is likely to confound&#xD;
             interpretation of drug effect, affect cognitive assessments, or affect the subject´s&#xD;
             ability to complete the study&#xD;
&#xD;
          -  Subjects who are known to have autosomal dominant mutation-associated presenile AD&#xD;
&#xD;
          -  Subjects who show signs of AIDS (Acquired Immunodeficiency Syndrome), HBV (Hepatitis B&#xD;
             Virus), HCV (Hepatitis C), VDRL (Venereal Disease Research Laboratory)&#xD;
&#xD;
          -  Subjects who have any conditions that would contraindicate an MRI, such as the&#xD;
             presence metallic objects in the eyes, skin, or heart&#xD;
&#xD;
          -  Subjects who have &gt; 4 cerebral microhemorrhages (regardless of their anatomical&#xD;
             location or diagnostic characterization as &quot;possible&quot; or &quot;definite&quot;), a single area of&#xD;
             superficial siderosis, or evidence of a prior microhemorrhage as assessed by MRI&#xD;
&#xD;
          -  Subjects who have history of malignant cancer within the last 5 years (The following&#xD;
             is a partial list of conditions that are permissible for study entry: non-metastatic&#xD;
             basal and/or squamous cell carcinoma of the skin, in situ cervical, or non-progressive&#xD;
             prostate cancer)&#xD;
&#xD;
          -  Subjects who have suspected active lung disease based on chest X-ray&#xD;
&#xD;
          -  Subjects who are hypersensitive to fetal bovine serum or penicillin&#xD;
&#xD;
          -  Subjects who are currently using immunosuppressants, cytotoxic drug, corticosteroids&#xD;
             or similar steroidal anti-inflammatory medication (e.g., Prednisone) on a regular&#xD;
             basis (exceptions allowed include; regular use of steroidal nasal sprays, topical&#xD;
             steroids, and estrogen-replacement therapy)&#xD;
&#xD;
          -  Subjects for whom the investigator judges the liposuction can cause any problems&#xD;
&#xD;
          -  Subjects who have history of local anesthetic allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ATP Clinical Research</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valden Medical</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>June 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AstroStem</title>
          <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC) 2x10e8 cells</description>
        </group>
        <group group_id="P2">
          <title>Placebo-Control</title>
          <description>Saline with 30% auto-serum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AstroStem</title>
          <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
        </group>
        <group group_id="B2">
          <title>Placebo-Control</title>
          <description>Placebo-Control: Saline with 30% auto-serum</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.4" spread="7.6"/>
                    <measurement group_id="B2" value="75.6" spread="8.2"/>
                    <measurement group_id="B3" value="73.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.9" spread="14.4"/>
                    <measurement group_id="B2" value="168.3" spread="9.7"/>
                    <measurement group_id="B3" value="168.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="17.2"/>
                    <measurement group_id="B2" value="64.6" spread="12.0"/>
                    <measurement group_id="B3" value="69.9" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="4.3"/>
                    <measurement group_id="B2" value="22.8" spread="3.5"/>
                    <measurement group_id="B3" value="24.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Related Adverse Events</title>
        <description>Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results</description>
        <time_frame>30 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Adverse Events</title>
          <description>Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)</title>
        <description>Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)</title>
          <description>Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="6.8"/>
                    <measurement group_id="O2" value="3.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MMSE (Mini-mental Status Examination)</title>
        <description>Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>MMSE (Mini-mental Status Examination)</title>
          <description>Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.8"/>
                    <measurement group_id="O2" value="-1.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CDR-SOB (Clinical Dementia Rating-Sum of Boxes)</title>
        <description>Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>CDR-SOB (Clinical Dementia Rating-Sum of Boxes)</title>
          <description>Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.7"/>
                    <measurement group_id="O2" value="0.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NPI (Neuropsychiatric Inventory)</title>
        <description>Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>NPI (Neuropsychiatric Inventory)</title>
          <description>Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="8.5"/>
                    <measurement group_id="O2" value="-5.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GDS (Geriatric Depression Scale)</title>
        <description>Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>GDS (Geriatric Depression Scale)</title>
          <description>Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.3"/>
                    <measurement group_id="O2" value="0.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)</title>
        <description>Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)</title>
          <description>Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.</description>
          <population>3 of the 11 astrostem groups were dropped out and 1 was violated protocol.&#xD;
1 of the 10 Placebo-control groups was dropped out and 2 were violated protocol.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="9.0"/>
                    <measurement group_id="O2" value="-4.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-SSRS (Columbia Suicide Severity Rating Scale)</title>
        <description>Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.</description>
        <time_frame>Baseline and 30 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AstroStem</title>
            <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Control</title>
            <description>Placebo-Control: Saline with 30% auto-serum</description>
          </group>
        </group_list>
        <measure>
          <title>C-SSRS (Columbia Suicide Severity Rating Scale)</title>
          <description>Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="6.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AstroStem</title>
          <description>AstroStem: Autologous adipose tissue derived mesenchymal stem cells (AdMSC)</description>
        </group>
        <group group_id="E2">
          <title>Placebo-Control</title>
          <description>Placebo-Control: Saline with 30% auto-serum</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>oesophageal squamous cell carcinoma stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Open Angle Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abnormal Loss of Weight</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Nature Cell co., ltd</organization>
      <phone>02-545-4137</phone>
      <email>tin50@stemcellbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

